103 related articles for article (PubMed ID: 35970756)
41. Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.
Blombery P; Anderson MA; Gong JN; Thijssen R; Birkinshaw RW; Thompson ER; Teh CE; Nguyen T; Xu Z; Flensburg C; Lew TE; Majewski IJ; Gray DHD; Westerman DA; Tam CS; Seymour JF; Czabotar PE; Huang DCS; Roberts AW
Cancer Discov; 2019 Mar; 9(3):342-353. PubMed ID: 30514704
[TBL] [Abstract][Full Text] [Related]
42. SOHO State of the Art Updates and Next Questions | Mechanisms of Resistance to BCL2 Inhibitor Therapy in Chronic Lymphocytic Leukemia and Potential Future Therapeutic Directions.
Bennett R; Thompson E; Tam C
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):795-804. PubMed ID: 35970756
[TBL] [Abstract][Full Text] [Related]
43. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
44. Therapeutic targeting of apoptosis in chronic lymphocytic leukemia.
Ahn IE; Davids MS
Semin Hematol; 2024 Apr; 61(2):109-118. PubMed ID: 38538512
[TBL] [Abstract][Full Text] [Related]
45. Potential of BCL2 as a target for chronic lymphocytic leukemia treatment.
Moia R; Diop F; Favini C; Kodipad AA; Gaidano G
Expert Rev Hematol; 2018 May; 11(5):391-402. PubMed ID: 29561706
[TBL] [Abstract][Full Text] [Related]
46. How I treat chronic lymphocytic leukemia after venetoclax.
Lew TE; Tam CS; Seymour JF
Blood; 2021 Aug; 138(5):361-369. PubMed ID: 33876212
[TBL] [Abstract][Full Text] [Related]
47. Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia.
Roberts AW; Stilgenbauer S; Seymour JF; Huang DCS
Clin Cancer Res; 2017 Aug; 23(16):4527-4533. PubMed ID: 28100580
[TBL] [Abstract][Full Text] [Related]
48. SOHO State of the Art Updates and Next Questions: Understanding and Overcoming Venetoclax Resistance in Hematologic Malignancies.
Forsberg M; Konopleva M
Clin Lymphoma Myeloma Leuk; 2024 Jan; 24(1):1-14. PubMed ID: 38007372
[TBL] [Abstract][Full Text] [Related]
49. Genomics of Resistance to Targeted Therapies.
Thangavadivel S; Woyach JA
Hematol Oncol Clin North Am; 2021 Aug; 35(4):715-724. PubMed ID: 34174982
[TBL] [Abstract][Full Text] [Related]
50. Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies.
Roberts AW; Huang D
Clin Pharmacol Ther; 2017 Jan; 101(1):89-98. PubMed ID: 27806433
[TBL] [Abstract][Full Text] [Related]
51. Venetoclax for the Treatment of Chronic Lymphocytic Leukemia.
Eradat H
Curr Hematol Malig Rep; 2019 Oct; 14(5):469-476. PubMed ID: 31512151
[TBL] [Abstract][Full Text] [Related]
52. Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment.
Vogler M; Walter HS; Dyer MJS
Br J Haematol; 2017 Aug; 178(3):364-379. PubMed ID: 28449207
[TBL] [Abstract][Full Text] [Related]
53. BCL-2 Inhibitors, Present and Future.
Ryan CE; Davids MS
Cancer J; 2019; 25(6):401-409. PubMed ID: 31764121
[TBL] [Abstract][Full Text] [Related]
54. Venetoclax as a therapeutic option for the treatment of chronic lymphocytic leukemia: the evidence so far.
Held L; Siu C; Shadman M
Expert Opin Pharmacother; 2021 Apr; 22(6):655-665. PubMed ID: 33645381
[TBL] [Abstract][Full Text] [Related]
55. Venetoclax in the treatment of chronic lymphocytic leukemia.
Korycka-Wolowiec A; Wolowiec D; Kubiak-Mlonka A; Robak T
Expert Opin Drug Metab Toxicol; 2019 May; 15(5):353-366. PubMed ID: 30969139
[TBL] [Abstract][Full Text] [Related]
56. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
[TBL] [Abstract][Full Text] [Related]
57. The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.
Lampson BL; Davids MS
Curr Hematol Malig Rep; 2017 Feb; 12(1):11-19. PubMed ID: 28116634
[TBL] [Abstract][Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
